Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Cervical Cancer · Renal Cancer · Urothelial Cancer
Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 1 N=27 Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
Breast Cancer · Pancreatic Cancer · Colorectal Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 3; 4; 5; 7 Participants
Phase 2 N=24 Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Melanoma · Skin Cancer · Cancer
Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 1 N=5 Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Conjunctival Neoplasms
Primary: Number of Patients Assessed for Safety and Tolerability — 5 participants
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 1 N=147 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Part 1 · MELANOMA · SCCHN
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1 — 0; 0; 0; 0 Percentage of Participants
Phase 2 N=24 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Melanoma · Skin Cancer
Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants
Phase 4 N=8 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Melanoma
Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change
Phase 2 N=150 Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
Primary: Recurrence-Free Survival (RFS) — 0.0; 0.0 months — p=0.070
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
N/A N=50 Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma
Recurrent Melanoma
Primary: Sentinel Lymph Nodes (SLN) Mapping — 25; 25; 25; 4 Sentinel lymph nodes
N/A N=59 Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
N/A N=43 Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.
Nevi
Primary: Frequency of BRAF Mutations Among Nevi — 6; 19 BRAF mutations
Phase 2 N=12 Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants
Phase 1 N=24 Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
Advanced Malignant Neoplasm · Metastatic Malignant Neoplasm · Unresectable Malignant Neoplasm
Primary: Number of Participants With Dose-Limiting Toxicity — 0; 1; 0; 0 Participants
Phase 1 N=198 Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
Advanced Solid Malignancies
Primary: Dose Escalation Phase: Maximum Tolerated Dose (MTD) — 6; 40; 9; 7 milligrams (mg)
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 1 N=50 Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
Melanoma · Metastatic Melanoma · Solid Tumor
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths — 4; 3; 3; 3 Participants
Phase 2 N=1,009 A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
Phase 2 N=30 Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Primary: Number of Patients Treated in Compliance With Protocol — 29 Participants
Phase 2 N=13 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Response Rate — 1; 2; 4 participants
Phase 1 N=27 An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
Malignant Melanoma
Primary: Maximum Tolerated Dose (MTD) of IMC-20D7S — 20 mg/kg q2w
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Malignant Brain Tumors
Primary: Number of Participants With Objective Response — 2; 2; 4; 19 Participants
N/A N=14 Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
Breast Cancer · Leptomeningeal Metastasis
Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants
N/A N=8 Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms
Breast Cancer
Primary: Assess the Ability of the HD PET/CT to Predict Final Histopathologic NAC Response.
Phase 1 N=39 IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Phase 2 N=20 A Pilot Study of Bevacizumab for Neoplastic Meningitis
Neoplastic Meningitis
Primary: Cerebrospinal Fluid (CSF) Response Rate: Percentage of Participants Positive for Tumor Cells — 93 percentage of participants